The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

SWOG pilot study confirms feasibility, acceptability of bowel symptom intervention studies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

In a pilot study, a telephone-based dietary intervention designed to improve bowel function was shown to be widely acceptable to participants who had had surgery for rectal cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Ruxolitinib improves CML’s response to standard TKI treatment

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib (Jakafi) to standard tyrosine kinase inhibitor treatment for patients with chronic-phase chronic myeloid leukemia significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment. Results were presented at the European School of Haematology’s 26th Annual John...

In Brief

OU Health Stephenson Cancer Center earns Center of Excellence for Rectal Cancer accreditation

OU Health Stephenson Cancer Center at the University of Oklahoma Health Sciences earned a three-year accreditation from the National Accreditation Program for Rectal Cancer, making it the only accredited program in Oklahoma and one of only three other accredited programs within a 500-mile radius to receive the accreditation from the quality program of the American College of Surgeons.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account